title: The influence of adjuvants on local recurrence rate in giant cell tumour of the bone.
abstract: BACKGROUND
  Intralesional surgery of giant cell tumour of the bone (GCT) may result in a high rate of local recurrence. The introduction of local adjuvants, such as cementation, cryosurgery or phenolization, has proved to be successful in the reduction of recurrence rates. This study presents the results of a single institution in surgery of GCT with an evolution in treatment strategies.
  
  
  METHODS
  Forty primary and 25 recurrent surgical procedures in 46 patients with GCT of the bone with a median follow-up of 72 months were reviewed retrospectively. The mean age was 32.6 years (range 13.6-57.9 years). Forty-seven curettages and 18 resections were performed. For the curettages, a large bone window was cut followed by high speed burring and bone grafting or cementation. In 34 of 47 curettages and 7 of 18 resections, phenol was additionally applied.
  
  
  RESULTS
  Two patients showed pulmonary metastasis, one died due to metastatic disease. In total, a third of the patients developed local recurrence (32.3%). This was evenly spread among primary and recurrent diesease (32.5% vs. 32%). Seven of 13 curettages without adjuvant recurred (53.9%), compared to 11 of 34 curettages with adjuvant phenol (32.4%). Three of 18 resections developed a recurrence (16.7%). No complications in respect to the use of phenol were seen.
  
  
  CONCLUSIONS
  Phenolization is a safe local adjuvant therapy for GCT. Although the recurrence rate was lower with the use of phenol, this drop was not significant. The comparable high recurrence rate in our study, even if phenol was used, might be due to the fact that curettage was our favoured treatment, even in cases with an extensive juxta-articular tumour. We recommend adjuvant phenolization in the treatment of GCT of the bone after thorough curettage in applicable cases, including where cementation is used for defect filling.
authors.affiliation: Department of Orthopaedics, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: M F
authors.initials: MF
authors.lastname: Pietschmann
authors.forename: R A
authors.initials: RA
authors.lastname: Dietz
authors.forename: S
authors.initials: S
authors.lastname: Utzschneider
authors.forename: A
authors.initials: A
authors.lastname: Baur-Melnyk
authors.forename: V
authors.initials: V
authors.lastname: Jansson
authors.forename: H R
authors.initials: HR
authors.lastname: Dürr
mesh_terms: D000277:Adjuvants, Pharmaceutic; D000293:Adolescent; D000328:Adult; D001843:Bone Cements / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000401:mortality / Q000628:therapy*; D002484:Cementation; D003452:Cryosurgery; D005260:Female; D018212:Giant Cell Tumor of Bone / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D019800:Phenol / Q000008:administration & dosage; D010636:Phenols / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000277:Adjuvants, Pharmaceutic; D001843:Bone Cements; D010636:Phenols; D019800:Phenol